Related Experiment Videos
Treatment of lower respiratory tract infections with ceftazidime
Abstract:
The aim of this study was to evaluate the efficacy and tolerance of ceftazidime in the treatment of patients with lower respiratory tract infection. Fifty patients were included. Most of the patients received 1.0 g ceftazidime im three times daily. Thirty-seven patients were cured and eight improved (90%). A pathogen was isolated in 19 cases, (sputum 14, blood 4 and pleural fluid 1). The micro-organism was eradicated from the sputum in all but two cases. The result was unassessable in one. One or more side-effects probably related to the drug were found in 15 patients (30%), pain at injection site (10), an allergic rash (2), diarrhoea (2), pyrexia (1) and dyspnoea (1). Abnormal laboratory tests were seen in seven patients, an elevation in liver enzymes (4), an elevation in urea (1), leucopenia and granulocytopenia (1) and haemolytic anaemia (1). Most of the side-effects were mild and transient but the drug was stopped in five cases. The diarrhoea was severe in one case and the granulocytopenia was noted at a check-up four months after the treatment.
Insights
Ceftazidime effectively treated lower respiratory tract infections in 90% of patients. While generally well-tolerated, some experienced mild side effects, with few requiring treatment discontinuation.
Area of Science:
- Infectious Diseases
- Pharmacology
- Internal Medicine
Background:
- Lower respiratory tract infections (LRTIs) pose a significant clinical challenge.
- Effective antibiotic therapy is crucial for managing LRTIs.
- Ceftazidime is a third-generation cephalosporin with broad-spectrum activity.
Purpose of the Study:
- To assess the efficacy of ceftazidime in treating patients with LRTIs.
- To evaluate the safety and tolerance profile of ceftazidime in this patient population.
Main Methods:
- A prospective study involving 50 patients diagnosed with LRTIs.
- Patients received ceftazidime (1.0 g intramuscularly thrice daily).
- Clinical outcomes (cure, improvement) and adverse events were monitored.
Main Results:
- A clinical response (cure or improvement) was observed in 90% of patients (37 cured, 8 improved).
- Pathogen eradication from sputum was achieved in most cases where organisms were identified.
- Adverse events occurred in 30% of patients, mostly mild and transient (e.g., injection site pain, rash, diarrhea).
- Abnormal laboratory tests were noted in 7 patients; severe diarrhea and granulocytopenia were reported in isolated cases.
Conclusions:
- Ceftazidime demonstrates high efficacy in treating lower respiratory tract infections.
- The antibiotic is generally well-tolerated, with a manageable side effect profile.
- Ceftazidime is a viable therapeutic option for LRTIs, though careful monitoring for adverse events is warranted.